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Abstract Ankylosing spondylitis (AS) is a chronic inflam-
matory rheumatic disease. Decreased bone mineral density
(BMD) is a common complication of AS, with a prevalence
range of 19 to 62 %. Many studies have shown decreased
BMD in AS with long disease duration, but only a few studies
investigated BMD in early AS. The prevalence of decreased
BMD in early disease stages of AS has not yet been clearly
described, and for that reason, we reviewed the literature
which describes the prevalence of decreased BMD in AS
patients with a short disease duration (<10 years). In this
review, we included articles which used the modified New
York criteria for the diagnosis of AS, included patients with a
disease duration of less than 10 years, and used the WHO
criteria for osteopenia and osteoporosis. Decreased BMD was
defined as a T score<−1.0, including both osteopenia and
osteoporosis. For this review, only articles that acquired
BMD data of lumbar spine and femoral neck by DXA were
used. The literature search provided us 35 articles of which 7
matched all our criteria, and they will be further outlined in
this review. The overall prevalence of decreased BMD of the
articles reviewed is 54 % (n0229/424) for lumbar spine and
51 % (n0224/443) for femoral neck. The prevalence of osteo-
penia vs. osteoporosis for lumbar spine is 39 vs. 16 % and for
femoral neck, 38 vs. 13 %. This review showed a high total
prevalence of 51–54 % decreased BMD and 13–16 %
osteoporosis in AS with a short disease duration. This high
prevalence was not to be expected in a relatively young and
predominantly male population. Further research is needed to
determine the clinical relevance of this low BMD by investi-
gating the relation between low BMD and vertebral and non-
vertebral fractures at this early stage in AS.
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Abbreviations
AS Ankylosing spondylitis
BMD Bone mineral density
DMARDs Disease-modifying antirheumatic drugs
DXA Dual x-ray absorptiometry
NSAIDs Nonsteroidal anti-inflammatory drugs
SD Standard deviation
SpA Spondylarthropathy
WHO World Health Organization
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory rheu-
matic disease of the axial skeleton, which is characterized by
low back pain and stiffness for more than 3 months that
improves with exercise, but is not relieved by rest. Other
important symptoms are restriction of motion of lumbar spine
and limitation of chest expansion. Typical radiological fea-
tures of AS are sacroiliitis on X-ray and bridging syndesmo-
phytes of the spine, which usually take many years to develop,
and besides that, not all AS patients develop these syndesmo-
phytes. The first symptoms usually arise at an age younger
than 30 years. Men are more often affected than women, and
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90–95 % of the AS patients are HLA-B27 positive. The
prevalence of AS ranges between 0.1 and 1.4 % in Europe
and is partly dependent on the prevalence of HLA-B27, which
differs in populations with different ethnic backgrounds [1–3].
Osteoporosis in terms of decreased bone mineral density
(BMD) is a common complication in AS patients. The
prevalence ranges from 19 to 62 % [4–6]. The decrease of
BMD can be found both in the hip as well as in the spine
and depends on disease duration and presence of syndesmo-
phytes of the spine [7, 8]. Besides osteoporosis, also verte-
bral fractures are an important complication of long-
standing AS. The prevalence described of known vertebral
fractures ranges between 1 and 19 %; however, usually most
of them remain unrecognized [4, 9–12]. In many cases,
neither the patient nor the physician is aware of this in-
creased fracture risk among the relatively young and pre-
dominantly male AS population which can result in delay of
diagnosis and complications.
Osteoporosis in AS with a long disease duration has been
well known for quite some time now [9, 13–17]. Currently,
the treatment options for AS have improved since the use of
TNF-blocking agents, and the diagnosis is made at an earlier
stage of the disease. The knowledge of the prevalence of
decreased BMD in this early group, however, is limited
despite the fact that a decrease of BMD increases the frac-
ture risk [8, 10, 18, 19]. For this reason, we decided to
review the literature in order to investigate the prevalence
of decreased BMD in patients with AS with a relatively
short disease duration (<10 years). Secondly, we focused
at the clinical relevance of low BMD in this early popula-
tion, especially in relation with the risk of vertebral frac-
tures, since vertebral fractures are a major and serious cause
of morbidity in long-standing AS patients.
Methods
All patients included in the studies we used for this review
had to fulfill the diagnosis of ankylosing spondylitis accord-
ing to the modified New York criteria [2]. BMD was defined
according to the established criteria of the World Health
Organization (WHO), which is based on data of postmeno-
pausal women as no criteria of osteopenia and osteoporosis
are available for males. Normal bone density was defined as
T score≥−1.0, osteopenia as −2.5<T score<−1.0, and oste-
oporosis as T score≤−2.5 [20, 21]. The T score corresponds
to the number of standard deviations (SD) from any result of
the peak bone mass. We defined “decreased or low BMD” in
this review as T score≤−1.0 SD, including both osteopenia
and osteoporosis.
For this review, disease duration was defined as “time
since diagnosis” according to the modified New York crite-
ria [2]. However, in most articles, the definition of disease
duration was not available or not clearly described, and
when described, in most cases “time since diagnosis” was
used as disease duration. Therefore, we decided that disease
duration (defined as “time since diagnosis”) of less than
10 years was the inclusion criterion for our search, and not
symptom duration (defined as “time since first symptoms”).
The diagnosis of AS, disease duration of less than 10 years,
and the outcome BMD with prevalence numbers were our
main inclusion criteria. For this review, we only used BMD
data of the articles that were acquired by dual X-ray absorpti-
ometry (DXA), and all other measurements performed were
left out. Furthermore, we only used measurements of the
lumbar spine and femoral neck. Other measurements will be
briefly mentioned.
The databases used were PubMed, MEDLINE, Embase,
and Google Scholar with the following free search terms:
“ankylosing spondylitis,” “osteoporosis,” and “bone mineral
density.” The search in PubMed was also performed with
these free terms as MeSH terms. In our search, we always
used the Boolean operator “AND.” Through Web of Sci-
ence, we looked at which other articles had quoted our main
articles. To expand our search even more, we also used the
references mentioned by the articles and reviews we found.
Case reports were excluded because they have primarily a
signaling function, and extrapolation from their results is not
valid.
Statistics
An analysis was made of the overall prevalence of decreased
BMD and for the particular location lumbar spine or femoral
neck. This was done by adding up the number of patients
having a decreased BMD at that particular location. Subse-
quently, the total number of patients found with decreased




A literature search was conducted using the databases and
search terms mentioned above. This global search provided
us with 35 articles [4, 7–10, 13, 14, 16–19, 22–45]. Using
the mentioned inclusion and exclusion criteria, 11 articles
were excluded because of an unknown disease duration or
disease durations longer than 10 years [9, 14, 16, 17, 34–39,
44]. Another 16 articles were left out because the prevalence
number was not described [5, 8, 10, 13, 18, 23, 25, 28–33,
40–42]. One article was excluded because it was a case
report [43]. One study investigated early SpA patients, but
the subgroup of early AS was clearly described and
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therefore also included in this review [19]. This resulted in
seven articles which matched all our criteria, and they will
be further outlined below (Table 1).
Population
Karberg et al. recruited 103 German AS patients [7]. Depen-
dent on disease duration, they divided their patients into three
groups—group 1, patients with disease duration of <5 years
(n027); group 2, patients with disease duration of 5–10 years
(n048); and group 3, patients with disease duration >10 years
(n028). For our review, we excluded group 3 because of a
disease duration of more than 10 years. The study group of
Aydin et al. contained 58 Turkish male patients with AS [24].
Two studies were performed in Korea: a study by Baek et al.
which included 76Koreanmenwith AS and a study byKim et
al. which included 60 AS patients [26, 27]. Thirty-nine French
white, male patients with AS were included in the study of
Dos Santos et al. [22]. In the study of Vasdev et al., 80 Indian
male AS patients were studied [45]. The last study included in
this review derived from our group by van der Weijden et al.
contains 94 Dutch early AS patients [19].
Detection techniques
All the studies included in this review used DXA to measure
BMD. Karberg et al. also used dual-energy quantitative
computed tomography and peripheral quantitative computed
tomography and compared these results with DXA [7].
Aydin et al. used DXA to measure BMD in the left proximal
femur (femoral neck, trochanter area, and total hip), and all
scans were analyzed by the same investigator [24]. BMD in
the proximal femur was also measured by Baek et al. [27].
They also measured BMD of the lumbar spine (L2–L4).
Kim et al. determined BMD at similar places, lumbar spine
(L1–L4) and femoral neck [26]. Karberg et al. performed
also the same measurements; they measured lumbar spine
(L2–L4) and femoral neck, just like van der Weijden et al.
[7, 19]. Dos Santos et al. used DXA to measure whole body
BMD and regional BMD of the head, arms, whole spine,
lumbar spine, pelvis, and legs [22].
Outcome
The majority of the 482 patients described in the seven
studies were male (87 %), with a mean age of 34.5 years
and a mean disease duration of 7.7 years (Table 1). The
mean prevalence of low BMD in the early stage of AS was
51 % (range, 16–75 %) for the femoral neck and 54 %
(range, 46–74 %) for the lumbar spine. The mean preva-
lence of osteopenia for the femoral neck was 38 % (range,
14–56 %) and 39 % (range, 31–45 %) for the lumbar spine.
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patients at the region of the femoral neck and in 16 %
(range, 8–29 %) of the lumbar spine.
Additional numbers were presented by Aydin et al., who
also reported low BMD in 57 % (n033/58) of the cases of
trochanter and 55 % (n032/58) of total hip [24]. Bone loss
was found in 40 patients (69 %) in at least one of three
regions (femoral neck, trochanter, and/or total hip). Overall,
22 % (n013) had osteoporosis and 47 % (n027) osteopenia
using the WHO criteria for osteoporosis. A lower frequency
of decreased BMD of femoral neck and trochanter was
found by Baek et al. [27]. The frequency they found was
16 % (n012/76) in femoral neck and 8 % (n06/76) in
trochanter. Vasdev et al. also studied BMD in femur tro-
chanter and Ward’s triangle [45]. In the femur trochanter,
they found 50 % osteopenia and 5 % osteoporosis, and in
Ward’s triangle, 31 % osteopenia and 2 % osteoporosis.
Description of risk factors of low BMD
Decreased BMD can occur due to several factors of which old
age and female gender are the most important ones. However
in early AS, most patients are younger than 40 years of age,
and therefore, high age does not seem to be the most important
risk factor in this group.
The studies described here dealt differently with the other
risk factors of lowBMD. Four out of the seven articles excluded
patients with common risk factors for osteoporosis, such as use
of glucocorticosteroids, hip fractures in the family, and immo-
bilization [22, 24, 27]. Aydin et al. also excluded patients using
NSAIDs and DMARDs in the last month, as well as different
types of secondary diseases that could cause decreased BMD
(i.e., endocrine or metabolic diseases, liver or renal diseases, hip
fractures in family, and extremity fractures in the patient).
Vasdev et al. and Dos Santos et al. [22, 45] also excluded
patients with secondary diseases with the latter also excluding
patients with alcohol and tobacco abuse. The remaining studies
used no exclusion criteria for their patient selection [7, 19, 26].
The presence of syndesmophytes in patients included in
the articles reviewed could be important since syndesmo-
phytes might falsely increase BMD measured by DXA. Dos
Santos et al. therefore excluded patients with syndesmo-
phytes [22]. The others described the percentage of syndes-
mophytes. Karberg et al. found 26 % syndesmophytes in
group 1 (n07) and 55 % in group 2 (n026), whereas Baek
et al. found 36 % syndesmophytes (n027) [7, 27]. Vasdev
et al. reported syndesmophyte formation in 23 % [45] of
their patients. Van der Weijden et al. mentioned in their article
that only very few patients had a small syndesmophyte which
probably could not have influenced their presented results
[19]. Aydin et al. and Kim et al. did not mention anything
about the presence of syndesmophytes [24, 26].
Another risk factor for osteoporosis is the postmenopausal
state of women. Kim et al., Karberg et al., and van derWeijden
et al. were the only ones who included women in their studies
[7, 19, 26]. The number of women in these studies was low,
15 % (n09, Kim et al.), 37 % (n010, Karberg et al. group 1),
35% (n017, Karberg et al. group 2), and 27% (n025, van der
Weijden et al.). In the first two studies, menopause was not
further pointed out in relation to the reported percentage of
decreased bone density. In the study of van der Weijden et al.,
only two women were postmenopausal, one of them with low
BMD and the other with normal BMD. Therefore, female
gender does not explain the high prevalence of low BMD in
the 482 patients reported in this review.
Discussion
The literature search for the prevalence of decreased BMD
and osteoporosis in AS within the first decade after diagnosis
revealed a high mean prevalence of decreased BMD between
51 % of the femoral neck and 54 % of the lumbar spine.
Moreover, the prevalence of osteoporosis was 16 % for lum-
bar spine and 13 % for femoral neck. This corresponds with
prevalence numbers found in long-standing AS patients. The
variation in prevalence in the studies reviewed is probably
mainly caused by differences in the presence or exclusion of
cases with risk factors for low BMD between the included
patients and the heterogeneity of the populations. However,
the fact that the various studies performed within different
populations show an almost equally raised prevalence of low
BMD strengthens the conclusion that high prevalence of low
BMD is already present at the early stages of AS. Obviously,
this might be clinically relevant since low BMD is related to
an elevated fracture risk in primary osteoporosis in postmen-
opausal women and men. In line with that, Cooper et al. and
Vosse et al. have shown that vertebral fracture risk is elevated
in patients with AS [31, 46].
Some limitations of this review must be mentioned. Our
choice of BMD outcome resulted in exclusion of several
articles. We choose to only include studies which gave WHO
defined T scores as well as a prevalence to be able to correctly
compare and summon BMD outcomes. Also, for decreased
BMD, we used the threshold of a T score<−1.0, as defined by
the WHO. In ISCD 2007, decreased BMD for males younger
than 50 years was described as a T score<−2.0. However, as all
studies used osteopenia (−2.5<T score<−1.0) or osteoporosis
(T score≤−2.5) as BMD outcome measure, we used the osteo-
penia cutoff point as “low BMD.”
The seven studies used for this systematic review were
conducted in different countries—Korea [26, 27], France
[22], Germany [7], Turkey [24], India [45], and The Nether-
lands [19]. These countries differ in background risks of
osteoporosis due to racial differences, dietary habits, and sun
exposure. The differences in prevalence of decreased BMD
between areas in a healthy population were shown by Lunt
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et al. They found that BMD of the spine appears to vary in 16
European populations, from 0.934 to 1.0670 g/cm2 in women
and from 1.047 to 1.262 g/cm2 in men [47–49]. Furthermore,
the background prevalence of AS differs among several
countries, roughly correlating with the prevalence of HLA-
B27 [1, 3]. Beside the genetic factors predisposing to AS, the
prevalence of decreased BMD in (early) AS is also influenced
by differences in environmental (risk) factors among
countries, i.e., vitamin D deficiency, smoking, low body mass
index, use of corticosteroids, and anti-TNF alpha therapy
[50–54]. Unfortunately, four of the studies reviewed excluded
patients with common risk factors for osteoporosis, while the
others did not. Besides that, the average participant number of
the studies presented was 69 patients which is a relatively
small number to extrapolate to a population prevalence [7, 19,
22, 24, 26, 27, 45].
Next to general risk factors for low BMD, also disease-
specific risk factors like high disease activity and inflamma-
tion are of influence on BMD [9, 13, 55]. Some authors
suggest that inflammation can explain the major part of the
etiology of decreased BMD with cytokines as interleukin-1
and TNF alpha as primary mediators [18, 23, 56–58], stating
that low BMD in AS patients with inflammatory back pain is
related to inflammation, whereas Aydin et al. as well as others
found that bone loss was related to low serum sex hormone
levels in AS [14, 24]. However, Bronson et al. were unable to
find a correlation between testosterone levels and decreased
BMD [15]. Remarkably, Karberg et al. found that more
patients with syndesmophytes had low BMD than those with-
out and therefore suggested that bone loss and bone growth
occur parallel, also in early stages of AS [7]. This could not be
confirmed by the study of van der Weijden et al. because very
few syndesmophytes were found in the early stage of disease
in combination with a high prevalence of low BMD (46 %)
[19]. In this study, high disease severity indicated by impaired
physical function (high BASMI and BASFI levels) and high
CRP levels appeared to be strongly associated with low BMD
ASwithin 8 years of onset. So, also in early AS, there seems to
be an important role for inflammation [19, 58].
A point worth mentioning regarding this review is the
definition of disease duration. In this review, disease dura-
tion was defined as the “time since diagnosis.” Aydin et al.
and van der Weijden et al. both mentioned in their articles
the duration from the “moment of diagnosis” and the dura-
tion from the “moment of first symptoms” (both <10 years)
[19, 24]. Karberg et al., however, defined disease duration as
the “time since first symptoms” (also <10 years) [7]. Be-
cause the definition of Karberg et al. would only have
shortened the disease duration (the mean delay between
onset of first symptoms and diagnosis can run up to 8–
10 years), this study was considered to be eligible for this
review [59–61]. And above that, the results from this study
showed already a high prevalence of decreased BMD,
which only indicates more that decreased BMD is already
present in the (very) early stages of AS.
Another point worth mentioning are the difficulties of
diagnosing osteoporosis in AS studies in general. This prob-
lem is due to the fact that DXA of lumbar spine has a low
sensitivity in detecting decreased BMD in AS patients with
a long disease duration due to occurrence of bridging syn-
desmophytes and ligamentous ossification that might in-
crease the density of the axial skeleton [8, 13, 28, 29]. The
studies used in our review reported different percentages of
patients with syndesmophytes varying between 7 and 55 %
[7, 19, 27, 45], whereas some others excluded patients with
syndesmophytes [22], and others did not address the issue of
syndesmophytes at all [24, 26]. The presence of syndesmo-
phytes could have falsely increased the BMD of lumbar
spine in these studies, but we found comparable prevalence
numbers of low BMD in the hip and spine, so probably the
relatively low numbers of syndesmophytes in this early
group did not influence the data considerably. But if it did,
the real BMD would have been even lower.
Considering the high prevalence of decreased BMD in
patients with early AS, the question arises whether or not
patients should be treated for this condition. The answer to
this question depends on the clinical relevance of this obser-
vation. LowBMDbecomes clinically relevant when it leads to
an increased risk of vertebral and nonvertebral fractures since
these fractures are a serious cause of morbidity and reduced
quality of life [62–64]. The link between decreased BMD and
fracture risk is well known for the general healthy population
[65]. In later stages of AS, the risk of vertebral fractures is also
significantly increased, and low BMD is an important risk
factor for that complication [9, 13–17, 33, 46]. Unfortunately,
there is still no consensus whether or not decreased BMD in
patients with early AS causes an increased fracture risk [9].
Very few and small studies have been performed in early AS.
Jun et al. and van der Weijden et al. found a positive correla-
tion between low BMD and vertebral fractures [25, 66]. Jun et
al. found a relation between fractures and femoral BMD,
whereas van der Weijden et al. found a relation with BMD
of the lumbar spine. Nevertheless, other studies found no
correlation with low BMD at all [10, 13].
Conclusion
These studies show a high prevalence of low BMD (be-
tween 51 and 54 %) and a prevalence of 13–16 % of
osteoporosis in AS patients within 10 years after diagnosis.
This high prevalence was not to be expected in a relatively
young and predominantly male population. No unambigu-
ous correlation between decreased BMD and vertebral frac-
ture risk could be demonstrated; therefore, further research
is needed to determine the clinical relevance of low BMD in
Clin Rheumatol (2012) 31:1529–1535 1533
early AS patients by investigating the relation with vertebral
and nonvertebral fractures in larger studies.
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